Collin Stewart Raises Price Target on Human Genome Sciences (HGSI), FDA Approval of Benlysta
Tweet Send to a Friend
Collins Stewart is maintaining their Buy rating and is placing a price target of $37 on shares of Human Genome ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
